maklogo
Market Research Report

Global Pharmaceutical Cannabis Market Insights, Size, and Forecast By Formulation (Oils, Tinctures, Capsules, Topicals, Edibles), By Type (Cannabidiol, Tetrahydrocannabinol, Cannabinol, Cannabigerol), By End Use (Hospitals, Homecare, Pharmaceuticals, Research Laboratories), By Application (Pain Management, Neurological Disorders, Cancer Treatment, Mental Health Disorders), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:54779
Published Date:Jan 2026
No. of Pages:234
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Pharmaceutical Cannabis Market is projected to grow from USD 12.8 Billion in 2025 to USD 45.3 Billion by 2035, reflecting a compound annual growth rate of 14.2% from 2026 through 2035. This substantial growth underscores the increasing acceptance and integration of cannabis derived medicines into mainstream healthcare. The market encompasses pharmaceutical grade cannabis products, including cannabinoid based drugs, medical cannabis flowers, and various formulations used for therapeutic purposes. Key market drivers include the accelerating legalization and decriminalization of cannabis for medical use across numerous jurisdictions, a growing body of scientific evidence supporting the efficacy of cannabinoids in treating a range of medical conditions, and increasing patient and physician awareness regarding the potential benefits of pharmaceutical cannabis. Furthermore, advancements in cultivation, extraction, and formulation technologies are enhancing product quality, consistency, and bioavailability, contributing significantly to market expansion. The market is segmented by Application, Type, Formulation, and End Use, providing a granular view of its diverse landscape.

Global Pharmaceutical Cannabis Market Value (USD Billion) Analysis, 2025-2035

maklogo
14.2%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

Important trends shaping the market include a heightened focus on research and development to identify new therapeutic applications and optimize existing treatments, leading to a proliferation of innovative product offerings. There is also a notable shift towards standardized, pharmaceutical grade products, moving away from less regulated forms of medical cannabis. Strategic alliances, mergers, and acquisitions among pharmaceutical companies and cannabis firms are becoming increasingly common, aiming to consolidate market position and leverage expertise. However, the market faces several restraints, including complex and often inconsistent regulatory frameworks across different regions, which can impede market access and product development. Social stigma associated with cannabis, despite its medical applications, continues to be a hurdle, alongside challenges related to supply chain stability and quality control. Pricing pressures and the need for robust clinical trials to further validate efficacy and safety also present significant barriers to entry and expansion.

Despite these challenges, the market offers substantial opportunities. The emergence of new medical conditions for which cannabis therapies show promise, such as neurodegenerative diseases and certain types of cancer, represents a significant growth avenue. Expanding into emerging markets, particularly those with evolving regulatory landscapes, presents lucrative prospects. Furthermore, the development of synthetic cannabinoids and targeted delivery systems could unlock novel therapeutic applications and improve patient outcomes. North America currently dominates the market, primarily due to early legalization trends, well established medical cannabis programs, and a strong research infrastructure. However, Asia Pacific is poised to be the fastest growing region, driven by progressive changes in regulatory policies, increasing patient populations, and rising awareness of medical cannabis benefits in countries like Australia and Thailand. Key players such as Tilray, MedMen Enterprises, Hexo, Aurora Cannabis, Trulieve, Aphria, Cronos Group, GW Pharmaceuticals, Organigram, and Cresco Labs are actively pursuing strategies centered on product innovation, market expansion, and strategic partnerships to capitalize on these opportunities and maintain competitive advantage. The Pain Management segment leads the market, highlighting the substantial demand for cannabis based solutions in addressing chronic and acute pain conditions.

Quick Stats

  • Market Size (2025):

    USD 12.8 Billion

  • Projected Market Size (2035):

    USD 45.3 Billion

  • Leading Segment:

    Pain Management (42.5% Share)

  • Dominant Region (2025):

    North America (48.2% Share)

  • CAGR (2026-2035):

    14.2%

Global Pharmaceutical Cannabis Market Emerging Trends and Insights

Precision Dosing Innovations Driving Cannabis Therapeutics

Cannabis therapeutics are rapidly evolving, driven by innovations in precision dosing. This trend emphasizes moving beyond traditional consumption methods toward controlled, accurate delivery of cannabinoids. Pharmaceutical companies are investing heavily in technologies like microencapsulation, transdermal patches, and inhalers that offer exact dosages, ensuring consistent therapeutic effects. This approach minimizes side effects and maximizes efficacy by tailoring cannabis compounds to specific patient needs and conditions. The focus is on creating pharmaceutical grade products with standardized potency and bioavailability, enabling doctors to prescribe cannabis with confidence and predictability. This shift addresses previous challenges with variable potency and absorption, propelling cannabis into mainstream medicine as a reliable and effective treatment option. Ultimately, precision dosing innovations are professionalizing cannabis therapeutics, unlocking its full potential within healthcare.

Standardized Botanical Drug Development Accelerating Global Access

Standardized botanical drug development is rapidly accelerating global access to pharmaceutical cannabis. This trend emphasizes rigorous scientific methods for cultivating, extracting, and processing cannabis plants to ensure consistent purity, potency, and quality. Instead of relying on variable raw plant material, the focus is on isolating and precisely quantifying specific cannabinoids and other bioactive compounds. This allows for the creation of well defined pharmaceutical products with reliable dosages and predictable therapeutic effects. Regulatory bodies globally are increasingly accepting these standardized approaches, paving the way for easier market entry and broader medical prescription. This shift from loosely regulated herbal products to precisely formulated botanical drugs is transforming the global landscape, making pharmaceutical cannabis a more mainstream and accessible treatment option worldwide.

Psychedelic Pharmaceutical Blends Reshaping Mental Health

Psychedelic pharmaceutical blends are transforming mental healthcare within the global cannabis market. This trend sees the integration of regulated cannabis compounds with classic psychedelics like psilocybin or MDMA. Researchers are exploring novel formulations that leverage cannabis’s anxiolytic and anti inflammatory properties to potentially mitigate side effects of psychedelics and enhance therapeutic outcomes. These sophisticated blends aim to create safer more tolerable experiences for patients undergoing psychedelic assisted therapy. The focus is on developing precise dosages and delivery mechanisms for conditions such as PTSD depression and addiction. This innovative approach seeks to optimize efficacy and expand accessibility to these powerful new treatments moving beyond recreational use towards rigorously tested medical applications within a regulated framework.

What are the Key Drivers Shaping the Global Pharmaceutical Cannabis Market

Evolving Regulatory Landscape & Medical Acceptance

The global pharmaceutical cannabis market is significantly driven by a continually evolving regulatory landscape and increasing medical acceptance. Historically, cannabis faced strict prohibitions worldwide, limiting its research and therapeutic application. However, a growing body of scientific evidence supporting its efficacy in treating various conditions like chronic pain, epilepsy, multiple sclerosis, and chemotherapy induced nausea has prompted a reevaluation by governments. This shift is translating into the legalization of medical cannabis in more regions, establishing clearer frameworks for its cultivation, processing, and prescription. As regulatory bodies develop standardized guidelines for quality control, dosage, and product safety, physician confidence in prescribing cannabis derived medications grows. Furthermore, patient awareness of cannabis’s therapeutic potential is expanding, fueling demand and pushing for broader insurance coverage, all contributing to substantial market expansion.

Accelerated Clinical Research & Product Development

Accelerated clinical research and product development is a key driver in the global pharmaceutical cannabis market. Increased investment in scientific studies is rapidly validating the therapeutic potential of cannabinoids for diverse medical conditions. This acceleration stems from growing physician interest, expanding patient demand, and evolving regulatory landscapes that facilitate research. Companies are quickly developing and launching novel cannabis derived pharmaceuticals targeting specific diseases, ensuring high purity, precise dosing, and consistent efficacy. The focus on robust clinical trials builds trust and provides the necessary evidence for widespread adoption by healthcare professionals and inclusion in treatment protocols. This swift development cycle shortens time to market for innovative cannabis therapies.

Increasing Patient Demand & Physician Awareness

Growing patient populations are increasingly seeking alternative therapies for chronic pain, neurological disorders, and mental health conditions. Traditional pharmaceuticals often come with undesirable side effects or limited efficacy, prompting individuals to explore cannabis based treatments. Concurrently, physician awareness is expanding through clinical research and educational initiatives highlighting cannabis therapeutic potential. Healthcare providers are becoming more comfortable recommending medical cannabis as a viable option, particularly in jurisdictions with established regulatory frameworks. This dual rise in patient inquiry and physician acceptance is significantly propelling the pharmaceutical cannabis market forward, fostering greater adoption and reducing historical stigma associated with cannabis use in a medical context. It creates a positive feedback loop.

Global Pharmaceutical Cannabis Market Restraints

Regulatory Hurdles and Legal Ambiguity Restricting Market Access

Varying global regulations create significant barriers to entry for pharmaceutical cannabis companies. Countries possess disparate stances on cannabis legality, medical use, and product classifications, leading to a fragmented market. Manufacturers face complex and often conflicting requirements for product registration, clinical trials, and manufacturing standards across different jurisdictions. This regulatory labyrinth necessitates costly and time-consuming efforts to navigate diverse legal frameworks, from national drug control laws to regional medical cannabis programs. The absence of harmonized international standards and the prevalence of nationalistic approaches impede cross border trade and investment. Ambiguous legal definitions and inconsistent enforcement further complicate market access, discouraging innovation and limiting the availability of these products to patients globally.

Lack of Standardized Clinical Trials and Efficacy Data Hindering Adoption

The absence of consistent research methodologies poses a significant obstacle to the global pharmaceutical cannabis market. Without standardized clinical trials, there is a pervasive lack of robust efficacy data across different cannabis products and formulations. This inconsistency makes it challenging for healthcare professionals to confidently prescribe cannabis-based medicines, as reliable evidence of their therapeutic benefits and optimal dosages is scarce. Furthermore, the varying quality and design of existing studies lead to conflicting results, eroding trust among medical practitioners, regulators, and the public. This data deficit directly hinders wider adoption because robust, comparable evidence of safety and efficacy is crucial for regulatory approval, insurance coverage, and mainstream medical integration.

Global Pharmaceutical Cannabis Market Opportunities

Developing Precision Cannabis-Based Therapeutics for Neuropathic Pain and Spasticity

The opportunity centers on scientifically developing precision cannabis based therapeutics to specifically alleviate neuropathic pain and spasticity. These debilitating conditions present substantial unmet medical needs globally, offering a significant patient population seeking effective treatment alternatives. By meticulously identifying optimal cannabinoid ratios, isolation techniques, and advanced delivery systems, pharmaceutical companies can create highly targeted medicines. This precision approach ensures enhanced efficacy, reduced side effects, and predictable patient outcomes, distinguishing these products in a rapidly evolving market. The Asia Pacific region, demonstrating the fastest growth in medical cannabis adoption and regulatory maturity, provides an especially promising landscape for introducing and expanding these specialized, evidence based cannabis derived solutions. This strategic focus on pharmaceutical grade innovation addresses critical therapeutic gaps, driving both patient benefit and market leadership.

Capitalizing on Regulatory Harmonization to Expand Pharmaceutical Cannabinoid Market Access

Regulatory harmonization across global markets presents a significant opportunity for the pharmaceutical cannabinoid sector. As nations increasingly align their medical cannabis laws and product standards, companies can streamline product development, clinical trials, and regulatory submissions. This convergence reduces market fragmentation, lowering costs and complexities associated with entering diverse jurisdictions. Businesses can leverage unified regulatory frameworks to accelerate market access for their pharmaceutical cannabinoid therapies, reaching a wider patient base more efficiently. It fosters an environment where products approved in one region might more easily gain acceptance elsewhere, particularly in emerging high growth areas. This strategic alignment minimizes the need for redundant studies and local adaptations, allowing for greater investment in innovation and global expansion. Capitalizing on this trend means developing products with international standards in mind from conception, enabling smoother market penetration and a more predictable global commercial landscape for cannabinoid-based medicines. This enhances patient access to vital treatments.

Global Pharmaceutical Cannabis Market Segmentation Analysis

Key Market Segments

By Application

  • •Pain Management
  • •Neurological Disorders
  • •Cancer Treatment
  • •Mental Health Disorders

By Type

  • •Cannabidiol
  • •Tetrahydrocannabinol
  • •Cannabinol
  • •Cannabigerol

By Formulation

  • •Oils
  • •Tinctures
  • •Capsules
  • •Topicals
  • •Edibles

By End Use

  • •Hospitals
  • •Homecare
  • •Pharmaceuticals
  • •Research Laboratories

Segment Share By Application

Share, By Application, 2025 (%)

  • Pain Management
  • Neurological Disorders
  • Cancer Treatment
  • Mental Health Disorders
maklogo
$12.8BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is Pain Management dominating the Global Pharmaceutical Cannabis Market?

Pain Management holds a commanding position as the largest application segment, accounting for a substantial share of the market. This dominance is primarily driven by the proven efficacy of cannabis compounds in managing chronic, neuropathic, and inflammatory pain, offering patients an alternative or complementary treatment option to traditional analgesics. The growing burden of chronic pain conditions worldwide and the desire for non-opioid pain relief solutions significantly propel demand within this application area.

Which cannabis type is crucial for market growth and why?

Cannabidiol, or CBD, is a crucial driver for market growth within the pharmaceutical cannabis sector. Its non-psychoactive properties, coupled with strong evidence of its therapeutic benefits across various conditions including pain, anxiety, and inflammation, make it highly appealing to both patients and healthcare providers. The widespread acceptance and decreasing stigma associated with CBD-based products contribute significantly to its adoption in diverse medical applications, fostering broader market expansion.

What end use settings are pivotal for pharmaceutical cannabis accessibility?

The accessibility of pharmaceutical cannabis is significantly influenced by its utilization across homecare and pharmaceutical settings. Homecare allows patients to manage their conditions conveniently under medical guidance, increasing adherence and quality of life. Pharmaceuticals represent the controlled and standardized development of cannabis-derived medicines, ensuring safety and efficacy through rigorous clinical trials and regulatory approval, thereby integrating these treatments into mainstream healthcare infrastructure.

Global Pharmaceutical Cannabis Market Regulatory and Policy Environment Analysis

The global pharmaceutical cannabis market navigates a complex patchwork of evolving regulations. While the United Nations still lists cannabis as a Schedule I drug, many nations are progressively decoupling their domestic policies. A significant trend involves countries establishing distinct medical cannabis programs, often requiring strict physician prescriptions for qualifying conditions. These frameworks typically mandate licensed cultivation, processing, and dispensing facilities.

Product quality and safety are paramount, leading to an increased focus on Good Manufacturing Practices GMP, stringent testing for potency and contaminants, and clear labeling requirements. Research and development for cannabis based medicines are generally encouraged but subject to rigorous clinical trial protocols. International trade remains heavily restricted, creating supply chain challenges. Advertising and marketing face tight constraints, preventing unsubstantiated health claims. Harmonization of standards is a long term goal, as the disparity in national laws creates significant market entry barriers and operational complexities for pharmaceutical companies. This fragmented landscape necessitates localized compliance strategies.

Which Emerging Technologies Are Driving New Trends in the Market?

The pharmaceutical cannabis market is experiencing robust expansion driven by significant innovation. Emerging technologies are revolutionizing drug delivery, enhancing therapeutic efficacy and patient compliance. Advanced formulations include microencapsulated cannabinoids and nanoparticle based systems, ensuring precise dosing and targeted action for conditions like chronic pain, epilepsy, and multiple sclerosis. Cultivation practices are evolving rapidly. Precision agriculture, using vertical farming and aeroponics, optimizes cannabinoid profiles and yield consistency. Biotechnology is exploring synthetic cannabinoids and bioengineered yeasts to produce rare phytocannabinoids economically and with high purity. AI and machine learning accelerate drug discovery and patient stratification, identifying optimal cannabinoid combinations for personalized medicine. Novel extraction methods, such as supercritical CO2 and solventless techniques, yield purer, more consistent active pharmaceutical ingredients. These advancements are critical for expanding therapeutic applications and global market penetration.

Global Pharmaceutical Cannabis Market Regional Analysis

Global Pharmaceutical Cannabis Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
48.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 48.2% share

North America undeniably dominates the global pharmaceutical cannabis market, commanding a significant 48.2% market share. This leadership stems from progressive regulatory frameworks in several US states and Canada, which have fostered a robust environment for medical cannabis research, development, and commercialization. The region benefits from substantial investment in sophisticated cultivation and processing technologies, alongside a wellestablished healthcare infrastructure capable of integrating cannabis based therapies. Furthermore, public acceptance and physician awareness regarding therapeutic applications of cannabis are higher in North America compared to other continents. This combination of supportive legislation, advanced infrastructure, and evolving societal perspectives firmly establishes North America as the primary growth driver and innovation hub for pharmaceutical cannabis worldwide.

Fastest Growing Region

Asia Pacific · 28.5% CAGR

Asia Pacific is poised to be the fastest growing region in the global pharmaceutical cannabis market, exhibiting a remarkable CAGR of 28.5% through 2035. This rapid expansion is driven by evolving regulatory landscapes in key economies like Australia and Thailand, which are progressively legalizing medical cannabis. Increasing physician and patient awareness regarding cannabis therapeutic benefits for chronic pain, epilepsy, and multiple sclerosis also fuels demand. Furthermore, growing investment in research and development by domestic pharmaceutical companies is accelerating product innovation and market penetration. The region’s large patient pool and rising disposable incomes further contribute to this robust growth trajectory, positioning Asia Pacific as a pivotal hub for pharmaceutical cannabis.

Impact of Geopolitical and Macroeconomic Factors

Geopolitical shifts impact the pharmaceutical cannabis market through varying national legalization frameworks and international trade regulations. Countries with established medical cannabis programs often become research and development hubs, attracting investment. However, stringent import export restrictions and the plant's Schedule I classification in many nations create significant supply chain hurdles and limit global market integration. Political instability in traditional cannabis producing regions could also disrupt raw material availability, potentially shifting production to more stable, regulated environments.

Macroeconomic forces further shape this nascent industry. High research and development costs for pharmaceutical applications and the capital intensive nature of large scale cultivation drive consolidation and require substantial external funding. Economic downturns could curtail consumer spending on expensive cannabinoid based medicines, while also potentially redirecting government funding for research towards other priorities. Inflationary pressures may increase production costs, impacting profit margins and the affordability of therapies.

Recent Developments

  • March 2025

    Tilray announced a strategic partnership with a leading European pharmaceutical distributor to expand the reach of their medical cannabis product line across key EU markets. This initiative focuses on streamlined logistics and enhanced market penetration for their cannabis-based therapies.

  • July 2024

    GW Pharmaceuticals, a subsidiary of Jazz Pharmaceuticals, unveiled positive Phase 3 clinical trial results for a novel cannabinoid-based drug targeting severe refractory epilepsy. This promising development paves the way for potential regulatory approval and market expansion into new therapeutic areas.

  • September 2024

    Aurora Cannabis completed the acquisition of a prominent German medical cannabis cultivation and distribution company. This acquisition significantly strengthens Aurora's supply chain and market share within the rapidly expanding German medical cannabis landscape.

  • February 2025

    Cresco Labs launched a new line of pharmaceutical-grade cannabis edibles specifically formulated for targeted pain management and sleep disorders. These products, backed by clinical research, aim to address unmet patient needs with precise dosing and consistent cannabinoid profiles.

Key Players Analysis

Key players like Tilray and Aurora Cannabis are dominant in cultivation and product development leveraging advanced greenhouse technologies. GW Pharmaceuticals leads in prescription cannabis medicines utilizing rigorous clinical trials. Trulieve and Cresco Labs focus on US state level expansion and retail distribution. Aphria Hexo and Cronos Group engage in strategic partnerships and international market penetration. MedMen targets premium retail experiences while Cronos Group explores innovative delivery systems all driving market growth through product diversification and wider patient access.

List of Key Companies:

  1. Tilray
  2. MedMen Enterprises
  3. Hexo
  4. Aurora Cannabis
  5. Trulieve
  6. Aphria
  7. Cronos Group
  8. GW Pharmaceuticals
  9. Organigram
  10. Cresco Labs
  11. Green Thumb Industries
  12. Columbia Care
  13. TerrAscend
  14. Harvest Health & Recreation
  15. Canopy Growth

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 12.8 Billion
Forecast Value (2035)USD 45.3 Billion
CAGR (2026-2035)14.2%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Application:
    • •Pain Management
    • •Neurological Disorders
    • •Cancer Treatment
    • •Mental Health Disorders
  • By Type:
    • •Cannabidiol
    • •Tetrahydrocannabinol
    • •Cannabinol
    • •Cannabigerol
  • By Formulation:
    • •Oils
    • •Tinctures
    • •Capsules
    • •Topicals
    • •Edibles
  • By End Use:
    • •Hospitals
    • •Homecare
    • •Pharmaceuticals
    • •Research Laboratories
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Pharmaceutical Cannabis Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
5.1.1. Pain Management
5.1.2. Neurological Disorders
5.1.3. Cancer Treatment
5.1.4. Mental Health Disorders
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Type
5.2.1. Cannabidiol
5.2.2. Tetrahydrocannabinol
5.2.3. Cannabinol
5.2.4. Cannabigerol
5.3. Market Analysis, Insights and Forecast, 2020-2035, By Formulation
5.3.1. Oils
5.3.2. Tinctures
5.3.3. Capsules
5.3.4. Topicals
5.3.5. Edibles
5.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
5.4.1. Hospitals
5.4.2. Homecare
5.4.3. Pharmaceuticals
5.4.4. Research Laboratories
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Pharmaceutical Cannabis Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
6.1.1. Pain Management
6.1.2. Neurological Disorders
6.1.3. Cancer Treatment
6.1.4. Mental Health Disorders
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Type
6.2.1. Cannabidiol
6.2.2. Tetrahydrocannabinol
6.2.3. Cannabinol
6.2.4. Cannabigerol
6.3. Market Analysis, Insights and Forecast, 2020-2035, By Formulation
6.3.1. Oils
6.3.2. Tinctures
6.3.3. Capsules
6.3.4. Topicals
6.3.5. Edibles
6.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
6.4.1. Hospitals
6.4.2. Homecare
6.4.3. Pharmaceuticals
6.4.4. Research Laboratories
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Pharmaceutical Cannabis Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
7.1.1. Pain Management
7.1.2. Neurological Disorders
7.1.3. Cancer Treatment
7.1.4. Mental Health Disorders
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Type
7.2.1. Cannabidiol
7.2.2. Tetrahydrocannabinol
7.2.3. Cannabinol
7.2.4. Cannabigerol
7.3. Market Analysis, Insights and Forecast, 2020-2035, By Formulation
7.3.1. Oils
7.3.2. Tinctures
7.3.3. Capsules
7.3.4. Topicals
7.3.5. Edibles
7.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
7.4.1. Hospitals
7.4.2. Homecare
7.4.3. Pharmaceuticals
7.4.4. Research Laboratories
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Pharmaceutical Cannabis Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
8.1.1. Pain Management
8.1.2. Neurological Disorders
8.1.3. Cancer Treatment
8.1.4. Mental Health Disorders
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Type
8.2.1. Cannabidiol
8.2.2. Tetrahydrocannabinol
8.2.3. Cannabinol
8.2.4. Cannabigerol
8.3. Market Analysis, Insights and Forecast, 2020-2035, By Formulation
8.3.1. Oils
8.3.2. Tinctures
8.3.3. Capsules
8.3.4. Topicals
8.3.5. Edibles
8.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
8.4.1. Hospitals
8.4.2. Homecare
8.4.3. Pharmaceuticals
8.4.4. Research Laboratories
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Pharmaceutical Cannabis Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
9.1.1. Pain Management
9.1.2. Neurological Disorders
9.1.3. Cancer Treatment
9.1.4. Mental Health Disorders
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Type
9.2.1. Cannabidiol
9.2.2. Tetrahydrocannabinol
9.2.3. Cannabinol
9.2.4. Cannabigerol
9.3. Market Analysis, Insights and Forecast, 2020-2035, By Formulation
9.3.1. Oils
9.3.2. Tinctures
9.3.3. Capsules
9.3.4. Topicals
9.3.5. Edibles
9.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
9.4.1. Hospitals
9.4.2. Homecare
9.4.3. Pharmaceuticals
9.4.4. Research Laboratories
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Pharmaceutical Cannabis Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
10.1.1. Pain Management
10.1.2. Neurological Disorders
10.1.3. Cancer Treatment
10.1.4. Mental Health Disorders
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Type
10.2.1. Cannabidiol
10.2.2. Tetrahydrocannabinol
10.2.3. Cannabinol
10.2.4. Cannabigerol
10.3. Market Analysis, Insights and Forecast, 2020-2035, By Formulation
10.3.1. Oils
10.3.2. Tinctures
10.3.3. Capsules
10.3.4. Topicals
10.3.5. Edibles
10.4. Market Analysis, Insights and Forecast, 2020-2035, By End Use
10.4.1. Hospitals
10.4.2. Homecare
10.4.3. Pharmaceuticals
10.4.4. Research Laboratories
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Tilray
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. MedMen Enterprises
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. Hexo
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Aurora Cannabis
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. Trulieve
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Aphria
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Cronos Group
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. GW Pharmaceuticals
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Organigram
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. Cresco Labs
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. Green Thumb Industries
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Columbia Care
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. TerrAscend
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis
11.2.14. Harvest Health & Recreation
11.2.14.1. Business Overview
11.2.14.2. Products Offering
11.2.14.3. Financial Insights (Based on Availability)
11.2.14.4. Company Market Share Analysis
11.2.14.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.14.6. Strategy
11.2.14.7. SWOT Analysis
11.2.15. Canopy Growth
11.2.15.1. Business Overview
11.2.15.2. Products Offering
11.2.15.3. Financial Insights (Based on Availability)
11.2.15.4. Company Market Share Analysis
11.2.15.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.15.6. Strategy
11.2.15.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 2: Global Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Type, 2020-2035

Table 3: Global Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Formulation, 2020-2035

Table 4: Global Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 5: Global Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 7: North America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Type, 2020-2035

Table 8: North America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Formulation, 2020-2035

Table 9: North America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 10: North America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 12: Europe Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Type, 2020-2035

Table 13: Europe Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Formulation, 2020-2035

Table 14: Europe Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 15: Europe Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 17: Asia Pacific Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Type, 2020-2035

Table 18: Asia Pacific Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Formulation, 2020-2035

Table 19: Asia Pacific Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 20: Asia Pacific Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 22: Latin America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Type, 2020-2035

Table 23: Latin America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Formulation, 2020-2035

Table 24: Latin America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 25: Latin America Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 27: Middle East & Africa Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Type, 2020-2035

Table 28: Middle East & Africa Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Formulation, 2020-2035

Table 29: Middle East & Africa Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 30: Middle East & Africa Pharmaceutical Cannabis Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Healthcare Market Research

Explore comprehensive market research reports covering all aspects of the Healthcare industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;